

## UNDERTAKING

To: British Columbia Securities Commission

Re: **Algernon Pharmaceuticals Inc. (the "Company")**  
**Final Short Form Prospectus dated September 30, 2019 (the "Prospectus")**  
**SEDAR Project No. 2937735**

Pursuant to section 4.2(a)(x) of National Instrument 44-101, the Company undertakes to file with the British Columbia Securities Commission a copy of any material contract to be entered into on or before the completion of the distribution to be made under the Prospectus and such filing will occur promptly upon execution by the parties thereto and in any event within seven days after the completion of the distribution.

DATED September 30, 2019

**ALGERNON PHARMACEUTICALS INC.**

*"Christopher J. Moreau"*

---

Christopher J. Moreau  
Chief Executive Officer